Drug Interaction Report
1 drug interaction and 4 additional warnings found for the following 2 drugs:
- eliglustat
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:eliglustat trofinetide
Applies to: eliglustat, trofinetide
Before using eliglustat, you should have received a test to determine your CYP450 2D6 genotype, which lets the doctor know whether or not you can take the medication and at what dosage.
Depending on your CYP450 2D6 genotype and what other medications you may be on, using eliglustat together with trofinetide may not be recommended at all, or a dosage adjustment of eliglustat may be needed.
Treatment with trofinetide can increase the blood levels of eliglustat. This may increase the risk of serious and potentially life-threatening cardiac side effects such as:
- irregular heart rhythm
- heart block
- cardiac arrest
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, slow heart rate, weak pulse, or heart palpitations during treatment with eliglustat.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:Food/Lifestyle eliglustat
Applies to: eliglustat
Do not consume grapefruit or grapefruit juice during treatment with eliglustat unless directed otherwise by your doctor.
Grapefruit juice can increase the blood levels of eliglustat to dangerous levels.
This may increase the risk of serious and potentially life-threatening cardiac side effects such as:
- irregular heart rhythm
- heart block
- cardiac arrest
Talk to your doctor if you have any questions or concerns.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, slow heart rate, weak pulse, or heart palpitations during treatment.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
3 potential interactionsApplies to: 3 conditions, including Heart Disease, Liver Disease, and Renal Dysfunction.
Heart Disease
Major:eliglustat
Eliglustat has a major potential interaction with Heart Disease.
The use of eliglustat is contraindicated in patients who are CYP2D6 extensive metabolizers or intermediate metabolizers taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor or those who are intermediate metabolizers or poor metabolizers taking a strong CYP3A inhibitor due to the risk of a significant increase in drug plasma concentrations. Eliglustat is predicted to cause increases in EKG intervals (PR, QTc, and QRS) at high plasma concentrations and could result in arrhythmias; therefore, its use is not recommended in patients with preexisting cardiac disease (congestive heart failure, recent myocardial infarction, heart block, arrhythmias), or long QT syndrome.
Liver Disease
Major:eliglustat
Eliglustat has a major potential interaction with Liver Disease.
The use of drugs eliglustat is contraindicated in patients with moderate or severe hepatic impairment and in those patients, who are CYP450 2D6 extensive metabolizers with mild hepatic impairment and taking a strong or moderate CYP450 2D6 inhibitor due to the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac intervals. This agent is contraindicated in patients who are CYP450 2D6 extensive metabolizers, intermediate metabolizers and taking a strong or moderate CYP450 2D6 inhibitor concomitantly with a strong or moderate CYP450 3A inhibitor. In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat is contraindicated in those patients with any degree of hepatic impairment or those taking a strong CYP450 3A inhibitor.
Renal Dysfunction
Major:eliglustat
Eliglustat has a major potential interaction with Renal Dysfunction.
The use of drugs eliglustat should be avoided in patients with end-stage renal disease (estimated creatinine clearance (eCrCl) less than 15 mL/min not on dialysis or requiring dialysis). No dosage adjustment is recommended in patients with mild, moderate, or severe renal impairment (eCrCl at least 15 mL/min). In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat should be avoided in those patients with any degree of renal impairment.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.